Senolytics

Senolytics are a class of selective therapeutics designed to induce apoptosis in non-dividing, pro-inflammatory 'zombie' cells to reverse age-related tissue dysfunction.

Senolytics target cellular senescence, a state where damaged cells stop dividing but remain metabolically active, secreting a toxic mix of inflammatory proteins known as the SASP. By inhibiting specific anti-apoptotic pathways (SCAPs) like BCL-xL and p21, these drugs force 'zombie' cells into programmed death without harming healthy neighbors. Clinical momentum is building through trials at the Mayo Clinic and firms like Unity Biotechnology, testing compounds such as Dasatinib, Quercetin, and UBX1325. Early human data shows promise in treating localized conditions like diabetic macular edema and systemic issues like idiopathic pulmonary fibrosis. With the global senolytics market projected to hit $12.3 billion by 2032, the shift from managing symptoms to clearing the cellular 'root cause' of aging is officially underway.

https://www.mayoclinic.org/medical-professionals/geriatrics/news/senolytic-drugs-from-discovery-to-translation/mac-20502123